Clinical Trial

Anti-Inflammatory Challenge in Schizophrenia

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to illuminate the biological underpinnings of negative symptoms in schizophrenia-particularly motivational impairments-by probing the link between systemic inflammation and neural activity in reward-related brain circuits. The primary goal of this study is to determine: * Ventral Striatum Activation: Assess how reward anticipation engages the ventral striatum in individuals with schizophrenia, both before and after an anti-inflammatory intervention. * Anterior Insula Activation: Examine how increasing effort demands modulate activity in the anterior insula under the same conditions.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-04-10; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2024-02-15
Trial Details
NCT Number NCT05823532
Lead Sponsor Emory University
Collaborators: National Institute of Mental Health (NIMH)
Conditions Schizophrenia
Enrollment 60 participants
Start Date 2024-04-18
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-03